Study design, materials and methods
A prospective clinical trial was conducted involving 55 patients with LUTS, who were randomized to receive either constant frequency (CF) or VF SNM treatment over a 12-week period. The efficacy of both modes was assessed using a comprehensive set of indicators, including Quality of Life (QoL), Visual Analogue Scale (VAS), and Overactive Bladder Symptom Score (OABSS). Logistic regression analysis was employed to identify patient characteristics that are predictive of better outcomes with the VF mode. A nomogram web tool was developed to assist clinicians in selecting the most appropriate SNM frequency mode for individual patients.
Interpretation of results
Research indicates that for LUTD patients, VF SNM offers higher clinical benefits without increased risks compared to constant frequency. Patients with milder symptoms, no neurogenic LUTD, lower OABSS, or lower BMI benefit more from VF. The nomogram web tool aids clinical decision-making, promoting precision medicine in LUTD treatment. Further research is needed to understand patient responses to different SNM frequencies.